Search

Your search keyword '"Bateman AR"' showing total 43 results

Search Constraints

Start Over You searched for: Author "Bateman AR" Remove constraint Author: "Bateman AR"
43 results on '"Bateman AR"'

Search Results

1. The relationship between cerebral blood flow and venous sinus pressure: can hyperemia induce idiopathic intracranial hypertension?

4. A Lumped Parameter Model Suggests That Infusion Studies Overestimate the Cerebrospinal Fluid Outflow Resistance in Normal Pressure Hydrocephalus.

5. Computational Fluid Dynamic Simulation of the Cerebral Venous System in Multiple Sclerosis and Control Patients: Are Hemodynamic Variances Evident in Multiple Sclerosis?

6. A lumped parameter modelling study of cerebral autoregulation in normal pressure hydrocephalus suggests the brain chooses to be ischemic.

7. Anemia in Idiopathic Intracranial Hypertension Increases Cerebral Blood Flow and the Intracranial Pressure.

9. A perspective on the evidence for glymphatic obstruction in spaceflight associated neuro-ocular syndrome and fatigue.

10. The dilated veins surrounding the cord in multiple sclerosis suggest elevated pressure and obstruction of the glymphatic system.

12. Syringomyelia Is Associated with a Reduction in Spinal Canal Compliance, Venous Outflow Dilatation and Glymphatic Fluid Obstruction.

13. Dilatation of the bridging cerebral veins in multiple sclerosis correlates with fatigue and suggests an increase in pressure.

15. Modelling of the dilated sagittal sinuses found in multiple sclerosis suggests increased wall stiffness may be a contributing factor.

16. Dilatation of the bridging cerebral cortical veins in childhood hydrocephalus suggests a malfunction of venous impedance pumping.

17. A perspective on spaceflight associated neuro-ocular syndrome causation secondary to elevated venous sinus pressure.

18. Quantified hemodynamic parameters of the venous system in multiple sclerosis: A systematic review.

19. Does the venous pressure theory of multiple sclerosis pathophysiology deserve a second chance?

20. Possible Markers of Venous Sinus Pressure Elevation in Multiple Sclerosis: Correlations with Gender and Disease Progression.

22. The relationship between cerebral blood flow and venous sinus pressure: can hyperemia induce idiopathic intracranial hypertension?

23. The Incidence of Transverse Sinus Stenosis in Multiple Sclerosis: Further Evidence of Pulse Wave Encephalopathy.

24. The incidence of obesity, venous sinus stenosis and cerebral hyperaemia in children referred for MRI to rule out idiopathic intracranial hypertension at a tertiary referral hospital: a 10 year review.

25. The incidence of significant venous sinus stenosis and cerebral hyperemia in childhood hydrocephalus: prognostic value with regards to differentiating active from compensated disease.

26. Differences in the Calculated Transvenous Pressure Drop between Chronic Hydrocephalus and Idiopathic Intracranial Hypertension.

27. Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma.

28. Characterization of Conserved Toxicogenomic Responses in Chemically Exposed Hepatocytes across Species and Platforms.

29. Importance of collection in gene set enrichment analysis of drug response in cancer cell lines.

30. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.

31. The role of systemic inflammatory and nutritional blood-borne markers in predicting response to neoadjuvant chemotherapy and survival in oesophagogastric cancer.

33. Viral antigen mediated NKp46 activation of NK cells results in tumor rejection via NK-DC crosstalk.

34. Rectal cancer staging post neoadjuvant therapy--how should the changes be assessed?

35. Hanging in the balance. KIR and their role in disease.

36. Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells.

37. Lack of specificity of cell-surface protease targeting of a cytotoxic hyperfusogenic gibbon ape leukaemia virus envelope glycoprotein.

38. Cancer gene therapy: Part 2. Candidate transgenes and their clinical development.

40. Gene therapy for prostate cancer: current status and future prospects.

41. Cancer gene therapy: developments to 2000.

42. Cancer-related thromboembolic disease in patients with solid tumours: a retrospective analysis.

43. Risk factors for pneumothorax during percutaneous Hickman line insertion in patients with solid and haematological tumours.

Catalog

Books, media, physical & digital resources